Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Iovance Biotherapeutics Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $67.455M Miss $72.402M Estimate

Author: Benzinga Newsdesk | November 06, 2025 08:00am
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 10.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $67.455 million which missed the analyst consensus estimate of $72.402 million by 6.83 percent. This is a 15.20 percent increase over sales of $58.555 million the same period last year.

Posted In: IOVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist